Recombinant human nerve growth factor: Phase Ib/II started

Dompe began the 24-week, double-blind, vehicle-controlled, Italian Phase Ib/II Lumos trial to evaluate 60 and 180 µg/mL rhNGF eye drops in about 50 patients. The product is also in the Phase I/II REPA...